Table 2.
Treatment characteristics
| |
Total metastases (108) |
Primary |
Range |
Recurrence |
Range |
|
|---|---|---|---|---|---|---|
| m=52 | m=56 | |||||
| GTV |
Median (ccm) |
1.0 |
0.1-19.0 |
2.0 |
0.1-29.2 |
|
| PTV |
Median (ccm) |
4.7 |
1.1-41.0 |
9.2 |
1.6-62.4 |
|
| Brain volume treated with 4 Gy (V4Gy) |
Median (ccm) |
18.4 |
0-55.3 |
16.6 |
0-68.7 |
|
| Duration of hfSRT |
Median (days) |
15 |
8-32 |
16 |
5-23 |
|
| Recurrence situation |
WBRT dose concepts |
|
|
|
[%] |
|
| |
- 10x3 Gy |
0 |
|
27 |
48.2 |
|
| |
- 15x2.5 Gy |
0 |
|
11 |
19.7 |
|
| |
- 15x2 Gy |
0 |
|
4 |
7.1 |
|
| |
- 20x2 Gy |
0 |
|
8 |
14.3 |
|
| |
- others |
0 |
|
6 |
10.7 |
|
| |
|
m |
[%] |
m |
[%] |
|
| Localization of brain metastases |
frontal/frontoparietal |
15 |
28.8 |
13 |
23.2 |
|
| |
temporal |
1 |
1.9 |
6 |
10.7 |
|
| |
parietal/occipital |
13 |
25.0 |
15 |
26.8 |
|
| |
central brain |
7 |
13.5 |
7 |
12.5 |
|
| |
brainstem |
3 |
5.8 |
2 |
3.6 |
|
| |
cerebellum |
8 |
15.4 |
11 |
19.6 |
|
| |
others |
5 |
9.6 |
2 |
3.6 |
|
| Dose concepts |
EQD2 (Gy) |
median GTV (ccm) |
|
|
|
|
| 10x3 Gy |
33 |
9.29 |
1 |
1.9 |
3 |
5.4 |
| 5x4 Gy |
23 |
4.00 |
|
0.0 |
3 |
5.4 |
| 7x4 Gy |
33 |
4.70 |
|
0.0 |
11 |
19.6 |
| 8x4 Gy |
37 |
2.75 |
2 |
3.8 |
4 |
7.1 |
| 9x4 Gy |
42 |
5.56 |
|
0.0 |
2 |
3.6 |
| 10x4 Gy |
47 |
4.50 |
7 |
13.5 |
2 |
3.6 |
| 4x5 Gy |
25 |
4.00 |
|
0.0 |
1 |
1.8 |
| 5x5 Gy |
31 |
2.00 |
|
0.0 |
5 |
8.9 |
| 6x5 Gy |
38 |
1.00 |
10 |
19.2 |
14 |
25.0 |
| 7x5 Gy |
44 |
0.87 |
22 |
42.3 |
4 |
7.1 |
| 5x6 Gy |
40 |
0.76 |
10 |
19.2 |
7 |
12.5 |
| total | 1.46 | 52 | 100.0 | 56 | 100.0 | |